WallStSmart

Dyne Therapeutics Inc (DYN)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DYN leads profitability with a 0.0% profit margin vs -2.1%. DYN appears more attractively valued with a PEG of 0.19. DYN earns a higher WallStSmart Score of 40/100 (F).

DYN

Hold

40

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DYN1 strengths · Avg: 10.0/10
PEG RatioValuation
0.1910/10

Growing faster than its price suggests

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DYN4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DYN

The strongest argument for DYN centers on PEG Ratio. PEG of 0.19 suggests the stock is reasonably priced for its growth.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : DYN

The primary concerns for DYN are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

DYN profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

DYN carries more volatility with a beta of 1.40 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

DYN generates stronger free cash flow (-112M), providing more financial flexibility.

Bottom Line

DYN scores higher overall (40/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dyne Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?